156 related articles for article (PubMed ID: 8747373)
1. Role of the pathologist in biomarker studies.
Wilkinson EJ; Hendricks JB
J Cell Biochem Suppl; 1995; 23():10-8. PubMed ID: 8747373
[TBL] [Abstract][Full Text] [Related]
2. Appraisal of intratumoral microvessel density, MIB-1 score, DNA content, and p53 protein expression as prognostic indicators in patients with locally confined renal cell carcinoma.
Gelb AB; Sudilovsky D; Wu CD; Weiss LM; Medeiros LJ
Cancer; 1997 Nov; 80(9):1768-75. PubMed ID: 9351546
[TBL] [Abstract][Full Text] [Related]
3. Prostatic intraepithelial neoplasia (PIN) and other prostatic lesions as risk factors and surrogate endpoints for cancer chemoprevention trials.
Bostwick DG; Aquilina JW
J Cell Biochem Suppl; 1996; 25():156-64. PubMed ID: 9027613
[TBL] [Abstract][Full Text] [Related]
4. Quantitative image analysis of MIB-1 immunoreactivity. A comparison with flow cytometric assessment of proliferative activity in invasive carcinoma of the breast.
Ostrowski ML; Chakraborty S; Laucirica R; Brown RW; Greenberg SD
Anal Quant Cytol Histol; 1995 Feb; 17(1):15-24. PubMed ID: 7766265
[TBL] [Abstract][Full Text] [Related]
5. Comparative long-term prognostic value of quantitative HER-2/neu protein expression, DNA ploidy, and morphometric and clinical features in paraffin-embedded invasive breast cancer.
Baak JP; Chin D; van Diest PJ; Ortiz R; Matze-Cok P; Bacus SS
Lab Invest; 1991 Feb; 64(2):215-23. PubMed ID: 1671789
[TBL] [Abstract][Full Text] [Related]
6. DNA ploidy, proliferation, and neu-oncogene protein overexpression in breast carcinoma.
Lee AK; Wiley B; Loda M; Bosari S; Dugan JM; Hamilton W; Heatley GJ; Cook L; Silverman ML
Mod Pathol; 1992 Jan; 5(1):61-7. PubMed ID: 1347424
[TBL] [Abstract][Full Text] [Related]
7. Oncoproteins and tumor progression in papillary thyroid carcinoma: presence of epidermal growth factor receptor, c-erbB-2 protein, estrogen receptor related protein, p21-ras protein, and proliferation indicators in relation to tumor recurrences and patient survival.
Akslen LA; Varhaug JE
Cancer; 1995 Nov; 76(9):1643-54. PubMed ID: 8635070
[TBL] [Abstract][Full Text] [Related]
8. Adenoid cystic carcinoma of the trachea and bronchus--a clinicopathologic study with DNA flow cytometric analysis and oncogene expression.
Lin CM; Li AF; Wu LH; Wu YC; Lin FC; Wang LS
Eur J Cardiothorac Surg; 2002 Oct; 22(4):621-5. PubMed ID: 12297183
[TBL] [Abstract][Full Text] [Related]
9. Analysis of Ki-67 antigen expression, DNA proliferative fraction, and survival in resected cancer of the pancreas.
Stanton KJ; Sidner RA; Miller GA; Cummings OW; Schmidt CM; Howard TJ; Wiebke EA
Am J Surg; 2003 Nov; 186(5):486-92. PubMed ID: 14599612
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of DNA cytometry in 281 premenopausal patients with lymph node negative breast carcinoma randomized in a control trial: multivariate analysis with Ki-67 index, mitotic count, and microvessel density.
Mandard AM; Denoux Y; Herlin P; Duigou F; van De Vijver MJ; Clahsen PC; van Den Broek L; Sahmoud TM; Henry-Amar M; van De Velde CJ
Cancer; 2000 Oct; 89(8):1748-57. PubMed ID: 11042570
[TBL] [Abstract][Full Text] [Related]
11. Strategies for phase II cancer chemoprevention trials: cervix, endometrium, and ovary.
Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Steele VE; Lubet RA; Sigman CC
J Cell Biochem Suppl; 1995; 23():1-9. PubMed ID: 8747372
[TBL] [Abstract][Full Text] [Related]
12. Inverted urothelial papilloma: is ploidy, MIB-1 proliferative activity, or p53 protein accumulation predictive of urothelial carcinoma?
Cheville JC; Wu K; Sebo TJ; Cheng L; Riehle D; Lohse CM; Shane V
Cancer; 2000 Feb; 88(3):632-6. PubMed ID: 10649258
[TBL] [Abstract][Full Text] [Related]
13. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
Ottesen GL
APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
[TBL] [Abstract][Full Text] [Related]
14. MIB1 proliferation index in breast infiltrating carcinoma: comparison with other proliferative markers and association with new biological prognostic factors.
González-Vela MC; Garijo MF; Fernández F; Val-Bernal JF
Histol Histopathol; 2001 Apr; 16(2):399-406. PubMed ID: 11332695
[TBL] [Abstract][Full Text] [Related]
15. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.
Greenwald P
J Cell Biochem Suppl; 1996; 25():29-36. PubMed ID: 9027595
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of MIB-1 in advanced ovarian carcinoma as determined using automated immunohistochemistry and quantitative image analysis.
Layfield LJ; Saria EA; Berchuck A; Dodge RK; Thompson JK; Conlon DH; Kerns BJ
J Surg Oncol; 1997 Dec; 66(4):230-6; discussion 236-7. PubMed ID: 9425325
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical assessment of tumor proliferation and volume of embryonal carcinoma identify patients with clinical stage A nonseminomatous testicular germ cell tumor at low risk for occult metastasis.
Albers P; Miller GA; Orazi A; Ulbright TM; Albers J; Donohue JP; Foster RS
Cancer; 1995 Feb; 75(3):844-50. PubMed ID: 7828136
[TBL] [Abstract][Full Text] [Related]
18. Endometrial neoplasia: prognostic significance of ploidy status.
Evans MP; Podratz KC
Clin Obstet Gynecol; 1996 Sep; 39(3):696-706. PubMed ID: 8862893
[TBL] [Abstract][Full Text] [Related]
19. The most promising surrogate endpoint biomarkers for screening candidate chemopreventive compounds for prostatic adenocarcinoma in short-term phase II clinical trials.
Bostwick DG; Burke HB; Wheeler TM; Chung LW; Bookstein R; Pretlow TG; Nagle RB; Montironi R; Lieber MM; Veltri RW
J Cell Biochem Suppl; 1994; 19():283-9. PubMed ID: 7529857
[TBL] [Abstract][Full Text] [Related]
20. Risk biomarkers and current strategies for cancer chemoprevention.
Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Malone WF; Steele VE; Lubet RA; Sigman CC
J Cell Biochem Suppl; 1996; 25():1-14. PubMed ID: 9027592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
